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Summary
The nuclear factor (NF)-jB transcriptional system is a major effector
pathway involved in inflammation and innate immune responses. The
flavonoid luteolin is found in various herbal extracts and has shown
anti-inflammatory properties. However, the mechanism of action and
impact of luteolin on innate immunity is still unknown. We report
that luteolin significantly blocks lipopolysaccharide (LPS)-induced IjB
phosphorylation/degradation, NF-jB transcriptional activity and inter-
cellular adhesion molecule-1 (ICAM-1) gene expression in rat IEC-18
cells. Using chromatin immunoprecipitation, we demonstrate that LPS-
induced RelA recruitment to the ICAM-1 gene promoter is significantly
reduced in luteolin-treated cells. Moreover, in vitro kinase assays show
that luteolin directly inhibits LPS-induced IjB kinase (IKK) activity in
IEC-18 cells. Using bone-marrow derived dendritic cells (BMDCs) isola-
ted from interleukin (IL)-10–/– mice or from recently engineered trans-
genic mice expressing the enhanced green fluorescent protein (EGFP)
under the transcriptional control of NF-jB cis-elements (cis-NF-
jBEGFP), we found that luteolin blocks LPS-induced IjB phosphoryla-
tion and IKK activity, and decreases EGFP, IL-12 and tumour necrosis
factor-a gene expression. Moreover, intraperitoneal administration of
luteolin significantly inhibited LPS-induced EGFP expression in both
peripheral blood mononuclear cells and splenocytes isolated from cis-
NF-jBEGFP mice. These results indicate that luteolin blocks LPS-induced
NF-jB signalling and proinflammatory gene expression in intestinal epi-
thelial cells and dendritic cells. Modulation of innate immunity by nat-
ural plant products may represent an attractive strategy to prevent
intestinal inflammation associated with dysregulated innate immune
responses.
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NIK, NF-jB-inducing kinase; NGS, non-immune goat serum; ChIP, chromatin immunoprecipitation; PBMC, peripheral blood
mononuclear cells; RBC, red blood cell; FACS, fluorescence-activated cell sorter; GST, glutathione S-transferase; SEM, standard
error of mean.
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Introduction
The intestinal mucosa is constantly exposed to a myr-
iad of antigens, including bacteria and bacterial prod-
ucts (lipopolysaccharide (LPS), peptidoglycans), viruses,
parasites and dietary antigens. The host has evolved
sophisticated mechanisms to maintain homeostasis in
the face of such a hostile environment.1–4 First and
foremost, the intestinal luminal contents are isolated
from the host by a single layer of cells, the intestinal
epithelial cells (IECs). These cells form a tight barrier
that prevents potential toxic luminal products from
breaching the mucosal layer and activating the under-
lying resident immune cells and/or gaining access to
the systemic blood circulation.2 In addition, an array of
regulatory mechanisms such as the production of anti-
inflammatory molecules (transforming growth factor
(TGF)-b, interleukin (IL)-10, etc.), immunoglobulin A
(IgA) synthesized by immune cells, and various mucins
produced by IECs participate in the maintenance of
host homeostasis.5–7
Among the immune cells present in the intestinal
mucosa, dendritic cells (DCs) play a pivotal role in
sampling enteric antigens and presenting various micro-
bial antigens to T lymphocytes, which then mature into
either effector and/or regulatory cells.8 The outcomes of
these interactions determine whether the intestine initi-
ates tolerance toward its luminal contents or conversely,
proceeds to trigger an inflammatory process. Dysregu-
lated and/or constant activation of innate immunity
leading to improper activation of effector T cells is asso-
ciated with the development of intestinal inflammatory
disorders such as inflammatory bowel diseases (IBD).9
Thus, DCs are at the interface of innate and adaptive
immunity and are active participants in intestinal
homeostasis.
IECs and DCs have the potential to trigger a pro-
inflammatory gene transcriptional programme when
challenged with the bacterial product LPS.10–12 This
genetic programme is activated through Toll-like recep-
tor (TLR)-4-induced signal transduction, which then
targets various down-stream effector pathways such as
the transcription factor nuclear factor (NF)-jB.13,14 This
transcription factor regulates the expression of numer-
ous pro-inflammatory and immune-related genes and is
a central constituent of many effector pathways induced
by the innate immune system. TLR-4-mediated signal
transduction operates through MyD88-dependent mech-
anisms involving IL-1 receptor-associated kinase (IRAK)
phosphorylation and recruitment of tumour necrosis
factor (TNF) receptor-associated factor-6 (TRAF6) and
TGF-b activated kinase-1 (TAK1).13,14 The signals then
converge upon the IjB kinase (IKK) complex, which
phosphorylates the NF-jB inhibitor IjB on serine resi-
dues 32 and 36 causing its ubiquitination and degrada-
tion. Elimination of IjB liberates NF-jB from its
inhibitory effect and permits the nuclear translocation
of the transcription factor, binding to jB-promoter ele-
ments and induction of gene transcription.15,16 Because
NF-jB promotes intestinal inflammation, targeting this
signalling pathway may represent a therapeutic avenue
for the treatment of intestinal inflammatory disorders.17
Complementary and alternative medicine (CAM)
regroups diagnostic and therapeutic approaches not
included within allopathic medicine. Among the various
CAM, ‘herbal medicine’ is the most popular and fastest
growing approach used to treat various ailments world-
wide, specifically in the United States.18 Herbal medicine
generally refers to extracts or active components
obtained from plants, barks, roots, leaves, flowers, and
fruit used to alleviate medical conditions. Although
these products have been used for centuries as remedies
to treat numerous medical conditions in various coun-
tries, lack of empirical data showing efficacy and mech-
anisms of action precludes their incorporation into
mainstream medicine. Interestingly, many pharmaceuti-
cal products currently available originated from plant
extracts (e.g. salicylate from willow bark, quinone from
cinchona, digitalis from foxglove leaves and taxol from
Taxus brevifolia), suggesting that some herbal extracts
may be effective in treating some medical conditions.19
Whether plant extracts modulate innate immune
responses and intestinal inflammatory disorders is not
clear.
Flavonoids are naturally occurring polyphenolic com-
pounds, present in many plants and plant-based foods that
possess potent antioxidant, anticarcinogenic, immuno-
modulating and antibacterial activities.20–23 For example,
the flavonoids curcumin and luteolin have anti-inflamma-
tory properties both in vivo and in vitro.24–28 With respect
to innate signalling, luteolin (30,40,5,7-tetrahydroxyflav-
one), a flavonoid found in many herbal extracts including
celery, green pepper, perilla leaf and seeds and chamomile,
inhibits LPS-induced TNF-a secretion by macrophages
in vitro and has anti-inflammatory activity in mice.28 In
addition, luteolin inhibits LPS-induced NF-jB activity in
rat-1 fibroblasts.27
However, the mechanism through which luteolin
mediates its anti-inflammatory effects is not completely
understood, much less its impact on innate signalling.
Using IECs and bone-marrow derived dendritic cells
(BMDCs), we investigated the effect of luteolin on LPS-
induced NF-jB signalling and proinflammatory gene
expression. We report that luteolin blocks the activation
of NF-jB signalling by targeting IKK in both cell types
in vitro, and in immune cells in vivo using novel trans-
genic mice expressing the enhanced green fluorescent
protein (EGFP) under the transcriptional control of
NF-jB cis-elements (cis-NF-jBEGFP). These findings
indicate that luteolin may represent a new class of
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flavonoid capable of inhibiting NF-jB activity both
in vivo and in vitro.
Materials and methods
Cell culture and treatment of IECs
The rat non-transformed small intestinal cell line IEC-18
(American Type Culture Collection CRL 1589, Manassas,
VA) was used between passages 5 and 15. Cells were
grown as described previously.29 Luteolin (Sigma, St
Louis, MO) was dissolved in dimethyl sulphoxide
(DMSO; Sigma) to a final concentration of 10 mm. Cells
were pretreated for 1 hr with various concentration of
luteolin (0–100 lm) or with DMSO vehicle (05%),
after which they were stimulated with LPS (10 lg/ml;
from Escherichia coli serotype O111:B4, Sigma), IL-1b
(10 ng/ml) or TNF-a (5 ng/ml) (both from R & D
Systems, Minneapolis, MN).
Animals
Cis-NF-jBEGFP mice (BALB/c background) and IL-10–/–
mice (C57BL/6 · 129/Ola mixed background) were used
between 8 and 10 weeks of age. Cis-NF-jBEGFP mice are
recently engineered transgenic mice which express the
EGFP under the transcriptional control of NF-jB cis-
elements.30 EGFP gene expression is specifically induced
by NF-jB inducers which correlates with RelA binding to
the transgene promoter, and responds in vivo to stimula-
tion with LPS and anti-CD3.30 Animal experiments were
performed in accordance with the guidelines of the insti-
tutional Animal Care and Use Committee of the Univer-
sity of North Carolina at Chapel Hill.
Isolation and culture of BMDCs
BMDCs were generated from the femur and tibia of
cis-NF-jBEGFP and IL-10–/– mice. Bone marrow cells
were flushed and depleted of red blood cells (RBC)
using RBC lysing buffer (Sigma), and then cultured in
ultra low-adherence 24-well plates (Costar, Corning,
NY) in complete media (RPMI-1640 supplemented
with 10% fetal calf serum, 2 mm l-glutamine, 50 lm
2-mercaptoethanol, 10 ng/ml murine recombinant gra-
nulocyte–macrophage colony-stimulating factor (GM-
CSF) and 10 ng/ml murine recombinant IL-4 (both
from PeproTech, Rocky Hill, NJ). Half of complete
media was refreshed on the 3rd and 5th day. On the
7th day of culturing, non-adherent cells were collected
as BMDCs. The resulting population was greater than
93% CD11c+ and CD11b+ as determined by flow
cytometry. Cells were stimulated with LPS (1 lg/ml)
for various times to determine the expression of IL-12
p40, TNF-a and EGFP.
Real-time reverse transcription–polymerase chain
reaction (RT–PCR) analysis and enzyme-linked
immunosorbent assay (ELISA)
RNA was isolated using Trizol (Invitrogen, Carlsbad,
CA), and 1 lg of total RNA was reverse-transcribed
as described previously.24 Real-time RT–PCR was per-
formed using an ABI Prism 7700 sequence detection sys-
tem (Applied Biosystems, Foster City, CA) with specific
primers for rat ICAM-1, mouse IL-12 p40 and mouse
TNF-a. As an endogenous control, 18S ribosomal RNA
primers were used. All primers were designed by Primer
Express v2.0 (Applied Biosystems). The primer sequences
used in the present study are shown in Table 1. PCR was
conducted using SYBR Green PCR Master Mix (Applied
Biosystems) according to the manufacturer’s instruction.
Thermal cycler conditions were as follows: one cycle
of 10 min, 95 C, and 40 cycles of denaturation (15 s,
95 C) and combined annealing/extension (1 min, 60 C).
The specificity of the amplicon was tested via melting
curve analysis. A serial dilution of an external standard
(positive samples; LPS treated) was used to generate a cal-
ibration curve to determine signal intensity of each sam-
ple according to their threshold cycle. The amplifications
were performed in triplicates and the data was normalized
to the 18S ribosomal subunit.
An ELISA for mouse IL-12 p40 and TNF-a was per-
formed using culture supernatants from luteolin-treated
BMDCs according to the manufacturer’s instructions
(R & D Systems).
Adenoviral infection and NF-jB-luciferase reporter assay
IEC-18 cells were infected for 16 hr with Ad5jB-LUC
as described previously.11 Where indicated IEC-18 cells
Table 1. Specific primer sequences used in the real-time RT–PCR
and chromatin immunoprecipitation
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were coinfected for an additional 12 hr with Ad5IjBaAA,
Ad5dnIKKb, or Ad5wtNIK at a multiplicity of infection
(m.o.i) of 50. The Ad5dnIKKb and Ad5wtNIK constructs
were described previously.31 The Ad5GFP containing GFP
was used as a viral negative control. The Ad5CMV-LUC
containing constitutively active cytomegalovirus (CMV)
promoter-driven luciferase was used as a luciferase repor-
ter control. The adenoviruses were washed off, and fresh
medium containing serum was added. Cells were stimula-
ted with LPS (10 lg/ml) for 12 hr in the presence or
absence of various concentration of luteolin. Cell extracts
were prepared using luciferase cell lysis buffer (PharMin-
gen, San Diego, CA). Luciferase assays were performed
using an Lmax luminometer microplate reader (Molecular
Devices, Sunnyvale, CA), and results were normalized for
extract protein concentrations measured with the Bio-Rad
protein assay kit (Bio-Rad).
Western blot analysis
IEC-18 cells and BMDCs were stimulated with LPS (1–
10 lg/ml) for various times (0–1 hr). The cells were lysed
in 1· Laemmli buffer, and 20 lg of protein was subjected
to electrophoresis on 10% sodium dodecyl sulphate
(SDS)–polyacrylamide gels as described previously.11
Where indicated IEC-18 cells and BMDCs were pretreated
for 1 hr with 50 lm luteolin. Anti-phosphoserine IjBa
(Cell Signalling, Beverly, MA), anti-IjBa (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-phosphoserine RelA
(S536, Cell Signalling), anti-IRAK-1 (a generous gift from
D. K. Miller, Merck), anti-p38 (Cell Signalling), anti-
phosphoserine p38 (Cell Signalling), anti-phosphoserine
Janus kinase (JNK; PharMingen), anti-NIK (Santa Cruz
Biotechnology), anti-IKK-b (Santa Cruz Biotechnology)
and anti-b-actin (ICN, Costa Mesa, CA) were used to
detect immunoreactive phospho-IjBa, IjBa, phospho-
RelA, IRAK-1, p38, phospho-p38, phospho-JNK, NIK,
IKK-b and b-actin, respectively, using an enhanced
chemiluminescence detection kit (Amersham Biosciences,
Arlington Heights, IL).
Immunofluorescence
Luteolin (50 lm)-pretreated IEC-18 cells were stimulated
with LPS (10 lg/ml) for 30 min, after which they were
fixed with 100% ice-cold methanol. RelA immunofluores-
cence was performed as described previously.24 Briefly,
cells were blocked with 10% non-immune goat serum
(NGS) for 30 min, then probed with rabbit anti-RelA
antibody (Rockland, Gilberville, PA; diluted 1 : 200) in
10% NGS for 45 min, followed by rhodamine isothio-
cyanate-conjugated goat anti-rabbit IgG antibody (Jack-
son ImmunoResearch, West Grove, PA; diluted 1 : 100)
in 10% NGS for 30 min. RelA was visualized with a
fluorescent light microscope.
Chromatin immunoprecipitation (ChIP) assay
After IEC-18 cells were stimulated with LPS (10 lg/ml)
for 30 min in the presence or absence of luteolin
(50 lm), cells were washed in cold phosphate-buffered
saline (PBS) and fixed by adding formaldehyde to a final
concentration of 1%. Nuclear extraction and chromatin
immunoprecipitation were performed as described previ-
ously.32 Briefly, cells were lysed after formaldehyde
fixation in L1 lysis buffer (50 mm Tris (pH 80), 2 mm
ethylenediaminetetra-acetic acid (EDTA), 01% Nonidet
P-40, and 10% glycerol) supplemented with protease
inhibitors. Nuclei were pelleted and resuspended in
300 ll of L2 lysis buffer (50 mm Tris (pH 80), 01%
SDS, and 5 mm EDTA). Chromatin was sheared by
sonication (three times for 10 s at one-fifth of maxi-
mum power), centrifuged, and diluted in dilution
buffer (50 mm Tris (pH 80), 5 mm EDTA, 02 m NaCl,
and 05% Nonidet P-40). Extracts were precleared for
3 hr with salmon sperm-saturated protein A/G-agarose
(ssProtein A/G). Immunoprecipitation was carried out
overnight at 4 using 5 ll of anti-phosphoserine RelA
(Cell Signalling). Immune complexes were collected with
ssProtein A/G for 30 min and washed three times in
washing buffer (20 mm Tris (pH 80), 01% SDS, 05 m
NaCl, 2 mm EDTA, and 1% Nonidet P-40) and once in
05 m LiCl, followed by three washes with TE buffer.
Immune complexes were extracted three times with
100 ll of extraction buffer (TE buffer containing 2%
SDS). DNA cross-links were reverted by heating for 8 hr
at 65. After proteinase K (100 lg for 2 hr) digestion,
DNA was extracted with phenol/chloroform and precipi-
tated in ethanol. DNA isolated from an aliquot of the
total nuclear extract was used as a loading control for
the PCR (input control). PCR was performed with total
DNA (1 ll, input control) and immunoprecipitated
DNA (2 ll) using the following rat ICAM-1 promoter-
specific primers, as shown in Table 1.
In vitro IKK and IRAK-1 kinase assay
IEC-18 cells were pretreated for 1 hr with luteolin
(50 lm) and then stimulated with LPS (10 lg/ml) for
20 min or infected with Ad5wtNIK (m.o.i 50) for 16 hr.
IKK activity on serine IjBa phosphorylation was deter-
mined by immunocomplex kinase assay as described pre-
viously.24,31 IEC-18 cells were lysed in Triton lysis buffer
containing protease and phosphatase inhibitors and
then cleared by cenrifugation at 18 000 g for 10 min.
Eight hundred micrograms of whole cell extract was
immunoprecipitated with anti-IKKc (Santa Cruz Biotech-
nology) or IRAK-1 (Santa Cruz Biotechnology)/protein-A
beads. The kinase reactions were performed by incubating
25 ll of kinase buffer containing 20 mm Hepes (pH 77),
10 mm MgCl2, 5 mm dithiothreitol, 50 lm ATP, and
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5 lCi of [c-32P]ATP (ICN) with GST-IjBa substrate
(amino acid 1–54; IKK activity) or buffer alone (IRAK-1
auto-phosphorylation) for 30 min at 30. Substrate pro-
tein was resolved by gel electrophoresis, and phosphate
incorporation was assessed by autoradiography and Phos-
phorImager analysis (Amersham Biosciences).
Alternatively, the effect of luteolin on IKK activity and
IRAK-1 auto-phosphorylation was directly measured.
Immunoprecipitated IKK complexes or IRAK-1 from LPS
(1–10 lg/ml)-stimulated IEC-18 cells and BMDCs were
incubated with various concentrations of luteolin or con-
trol DMSO vehicle, and the kinase reactions were per-
formed as described above.
Spectrofluorometry and flow cytometric analysis
BMDCs isolated from cis-NF-jBEGFP mice were lysed by
lysis buffer (50 mm Tris (pH 75), 5 mm EDTA, 02 m
NaCl, and 01% Nonidet P-40), and cellular debris was
removed by centrifugation at 13 000 g for 10 min. The
fluorescence of EGFP in cell lysates was measured using a
SpectraMax Gemini XS spectrofluorometer (Molecular
Devices), and results were normalized for extract protein
concentrations measured with the Bio-Rad protein assay
kit. The excitation and emission settings were 488 nm
and 509 nm, respectively.
For the detection of EGFP in peripheral blood
mononuclear cells (PBMCs) and splenocytes isolated
from cis-NF-jBEGFP mice, flow cytometry determin-
ation was performed as previously described.30 Briefly,
5 · 105 RBC-depleted PBMCs or splenocytes were
washed with fluorescence-activated cell sorting (FACS)
buffer and EGFP expression was measured on a FAC-
scan (Becton-Dickinson, Mountain View, CA) using the
FL1 channel to detect EGFP fluorescence. All flow cyto-
metric analyses were conducted on living cells within
30 min of isolation.
Cytotoxicity assay
BMDCs were incubated with various concentrations of
luteolin in the presence or absence of LPS. Cytotoxicity was
measured using the LIVE/DEAD Viability/Cytotoxicity Kit
(Molecular Probes, Eugene, OR) according to the manufac-
turer’s specifications. Positive control dead cells were
generated by treating IEC-18 cells or BMDCs with methanol
for 30 min. Fluorescence in cell samples was measured with
appropriate excitation and emission filters using a Spectra-
Max Gemini XS spectrofluorometer (Molecular Devices)
according to the manufacturer’s instructions.
In vivo LPS endotoxaemia study
Cis-NF-jBEGFP mice were pretreated intraperitoneally
with DMSO vehicle or luteolin (02 mg/kg, 100 ll) for
2 hr before the intraperitoneal challenge of LPS
(40 mg/kg, 100 ll) and killed 18 hr poststimulation.
Peripheral blood was obtained by cardiac puncture and
placed into a sodium heparin-coated vial. RBCs were
lysed using RBC lysing buffer and PBMCs were pelleted
by density-gradient centrifugation over Histopaque-1083
(Sigma) for 20 min at 800 g. Cells were resuspended in
FACS analysis buffer (01% BSA/001% sodium azide in
PBS) just prior to FACS analysis. Splenocytes were iso-
lated by flushing the spleen through a 70 lm cell strai-
ner (Becton-Dickinson, Franklin Lakes, NJ) and RBC
lysed as described above. Cells were pelleted and resus-
pended in FACS analysis buffer just prior to FACS
analysis.
Statistical analysis
All data were expressed as the means for a series of
experiments ± SEM. Data were analysed by non-paramet-
ric t-tests or Wilcoxon rank sum tests. A 2-tailed P-value
of <005 was considered statistically significant.
Results
Luteolin inhibits LPS-induced ICAM-1 mRNA
accumulation and NF-jB transcriptional activity
in IEC-18 cells
The flavonoid luteolin has been shown to possess anti-
inflammatory properties both in vitro and in vivo,
although the inhibitory mechanism is not completely
understood. We first analysed the effects of luteolin on
signal-induced ICAM-1 gene expression in the rat non-
transformed intestinal cell line IEC-18. Cells were pre-
incubated with luteolin (50 lm) for 1 hr, stimulated with
LPS (10 lg/ml) IL-1b and TNF-a (10 and 5 ng/ml,
respectively) for 1 hr and 4 hr and ICAM-1 gene expres-
sion was measured by semiquantitative RT–PCR using an
ABI Prism 7700 sequence detection system. As seen in
Fig. 1(a), LPS, IL-1b and TNF-a induced ICAM-1 mRNA
expression is inhibited by luteolin treatment (66, 56, and
63% inhibition at 1 hr poststimulation, respectively).
Moreover, LPS-induced ICAM-1 mRNA accumulation
is still inhibited 4 hr stimulation (48% inhibition). The
transcription factor NF-jB is a common down-stream
signal effector pathway utilized by LPS, IL-1b and TNF-a,
and plays an essential role in signal-induced ICAM-1 gene
expression in IEC.33 Therefore, we next sought to deter-
mine whether luteolin prevents LPS-induced NF-jB
activity. IEC-18 cells were infected for 16 hr with an
adenoviral vector encoding an NF-jB-luciferase reporter
gene (Ad5-jB-LUC), pretreated with various doses of
luteolin for 1 hr and then stimulated with LPS (10 lg/ml)
for 12 hr. In addition, cells were infected with Ad5Ij-
BaAA and Ad5dnIKKb to selectively block NF-jB activa-
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tion. As shown in Fig. 1(b), luteolin dose-dependently
inhibited LPS-induced NF-jB transcriptional activity in
IEC-18 cells. However, CMV promoter-driven luciferase
activity is not blocked by luteolin, suggesting that this fla-
vonoid is not inhibiting luciferase activity per se (data not
shown). As expected, Ad5IjBaAA and Ad5dnIKKb also
blocked LPS-induced NF-jB activity in IEC-18 cells.
Luteolin blocks LPS-induced IjBa phosphorylation/
degradation, RelA nuclear translocation, and NF-jB
recruitment to the ICAM-1 promoter in IEC-18 cells
To dissect the effect of luteolin of LPS-induced signal
transduction, we determined the phosphorylation levels of
various down-stream signalling proteins involved in NF-
jB activation using Western blot analysis. Figure 2(a)
shows that LPS strongly induced IjBa phosphorylation
(1st panel) and triggered IjBa degradation in IEC-18 cells
(2nd panel), which is blocked in luteolin-treated cells.
Recent studies have shown that RelA phosphorylation,
JNK and the p38 pathway increase NF-jB transcriptional
activity in various cell systems.34–37 We next tested the
effect of luteolin on LPS-induced RelA (S536), JNK and
p38 phosphorylation. As shown in Fig. 2(a) (3rd, 4th and
5th panels), LPS-induced RelA (S536), JNK and p38
phosphorylation were not inhibited by luteolin treatment.
These suggest that luteolin exerts some level of specificity
on LPS signal transduction in IEC-18 cells.
To measure the impact of luteolin-mediated inhibition
of IjBa phosphorylation and degradation on NF-jB
activation, we evaluated RelA nuclear translocation by
immunofluorescence. As seen in Fig. 2(b), luteolin signifi-
cantly inhibited LPS-induced RelA nuclear translocation


















































































Figure 1. Luteolin inhibits LPS-induced ICAM-1 mRNA accumula-
tion and NF-jB transcriptional activity in IEC-18 cells. (a) IEC-18
cells were pretreated with luteolin (50 lm) for 1 hr, and then stimu-
lated with LPS (10 lg/ml), IL-1b (10 ng/ml) or TNF-a (5 ng/ml) for
1 hr. Total RNA (1 lg) was extracted, reverse-transcribed, and
amplified with an ABI Prism 7700 sequence detection system using
specific rat ICAM-1 primers. Relative quantification was performed
by comparison of threshold cycles values of samples with 18S ribo-
somal RNA. mRNA levels are expressed as fold changes over control
determined as the mean of one experiment performed in triplicate.
Results are representative of three independent experiments.
(b) IEC-18 cells were infected for 16 hr with Ad5jB-LUC, and
cells were coinfected for an additional 12 hr with Ad5IjBaAA,
Ad5dnIKKb, and control Ad5GFP (m.o.i. of 50). Cells were stimula-
ted with LPS (10 lg/ml) for 12 hr in the presence or absence of
various concentrations of luteolin. Cell extracts were prepared, lucif-
erase assays performed on an Lmax microplate reader, and results
were normalized to extract protein concentrations. LPS-induced luci-
ferase activity is expressed as fold changes over control determined
as the mean and SEM of three independent experiments measured in















Veh LPS (10 µg/ml) LPS + Lut (50 µM)
Figure 2. Luteolin blocks LPS-induced IjBa phosphorylation/degra-
dation and RelA nuclear translocation. (a) IEC-18 cells were stimula-
ted with LPS (10 lg/ml) for various times (0–30 min). Where
indicated, IEC-18 cells were pretreated for 1 hr with luteolin (50 lm).
Total protein was extracted, and 20 lg of protein was subjected to
SDS–PAGE followed by phospho-IjBa, IjBa, phospho-RelA (S536),
phospho-JNK, phospho-p38, p38, and b-actin immunoblotting using
the ECL technique. Results are representative of three independent
experiments. (b) IEC-18 cells were pretreated with luteolin (50 lm)
for 1 hr, and then stimulated with LPS (10 lg/ml) for 30 min. RelA
localization was visualized using an anti-RelA primary antibody fol-
lowed by a rhodamine-conjugated detection antibody. This immuno-
fluorescence is representative of two independent experiments. Veh,
DMSO vehicle; Lut, Luteolin.
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is not present in the nucleus to induce gene transcription.
To address this possibility, we carried out ChIP analysis
of the ICAM-1 gene promoter using a phosphoserine
(536) RelA antibody. IEC-18 cells were stimulated with
LPS (10 lg/ml) in the presence or absence of luteolin
(50 lm), and RelA recruitment to the ICAM-1 promo-
ter region determined by PCR. As seen in Fig. 3,
LPS-induced RelA recruitment to the ICAM-1 promoter
was blocked by luteolin pretreatment. Similar levels of
ICAM-1 promoter were amplified from the total pool of
genomic DNA (input control), demonstrating that equal
amounts were used for the ChIP assay (Fig. 3, lower
panel). Non-specific IgG or protein A/Gbead alone
showed no signal (data not shown). These findings indi-
cate that luteolin blocks NF-jB signalling through inhibi-
tion of IjBa degradation, RelA nuclear translocation and
binding to the ICAM-1 gene promoter.
Luteolin directly inhibits LPS-induced IjB kinase
activity in IEC-18 cells
The above data indicates that luteolin inhibits a signalling
event leading to IjB phosphorylation. LPS-induced serine
IjBa phosphorylation is mediated by activation of the
IKK complex in numerous cell systems. To determine the
impact of luteolin on IKK activity, we performed an
in vitro kinase assay. IEC-18 cells were pretreated with
luteolin (50 lm), stimulated with LPS (10 lg/ml) for
20 min and IKKc was immunoprecipitated. IKKa/b
kinase activity was measured using GST-IjB (1–54) as a
substrate. As shown in Fig. 4(a), luteolin significantly
inhibited LPS-induced IKK activity in IEC-18 cells. Use of
non-specific IgG or no antibody-bead alone controls
showed no signal (data not shown).
To dissect in more detail the mechanism of luteolin-
mediated inhibition, we investigated the effect of this flavo-
noid on NIK-induced NF-jB activity. NIK has been
positioned as an up-stream kinase involved in activation of
the IKK complex. We recently showed that adenoviral gene
delivery of NIK (Ad5wtNIK) strongly induced IKK activity







Figure 3. Luteolin blocks LPS-induced NF-jB recruitment to the
ICAM-1 promoter in IEC-18 Cells. IEC-18 cells were stimulated with
LPS for 30 min in the presence or absence of luteolin (50 lm), and
ChIP assay was performed using an antiphospho-RelA antibody as
described under Materials and Methods. PCR was performed using
specific primers for the rat ICAM-1 promoter. Results are represen-
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Figure 4. Luteolin directly inhibits LPS-induced IjB kinase activity
in IEC-18 cells. (a) and (c), IEC-18 cells were pretreated with luteo-
lin (50 lm) for 1 hr, and then stimulated with LPS (10 lg/ml) for
20 min (a) or infected with Ad5wtNIK (m.o.i 50) for 16 hr (c).
Whole cell extract was immunoprecipitated with anti-IKKc/protein-
A beads and the kinase reaction was performed using GST-IjB
(1–54) as a substrate as described under ‘Materials and methods’.
Substrate protein was resolved by gel electrophoresis, and phosphate
incorporation was assessed by autoradiography and PhosphorImager
analysis. Coomassie Blue staining and Western blot for IKKb show
equal loading (2nd and 3rd blot, respectively). (b) IEC-18 cells were
coinfected with Ad5jB-LUC and Ad5wtNIK in the presence or
absence of luteolin (50 lm). Luciferase assay was measured using an
Lmax microplate reader, and results were normalized for extract pro-
tein concentrations. (d) to evaluate whether luteolin inhibits IKK or
IRAK-1 directly, immunoprecipitated IKK or IRAK-1 from LPS-
stimulated IEC-18 cells were aliquoted into kinase reaction buffer in
presence of various concentrations of luteolin or DMSO vehicle. IKK
or IRAK-1 assay was performed as described in the Materials and
Methods. These results are representative of at least two independent
experiments. Veh, DMSO vehicle; Lut, Luteolin.
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were coinfected with Ad5jB-LUC and Ad5wtNIK in the
presence or absence of luteolin (50 lm) and luciferase
activity measured. Ad5wtNIK induced a 21-fold increase
in NF-jB activity that was significantly suppressed in
luteolin-treated cells (Fig. 4b). To measure the impact of
luteolin on NIK-induced IKK activity, IEC-18 cells were
infected with Ad5wtNIK for 12 hr in the presence or
absence of luteolin. Ad5wtNIK significantly induced IKK
activity in IEC-18 cells, which was dose-dependently
blocked in luteolin-pretreated cells (Fig. 4c). Luteolin did
not decrease NIK expression in Ad5wtNIK-infected cells.
This suggests that luteolin acts at the level of, or down-
stream of NIK and might directly inhibit IKK activity.
To test this hypothesis, we directly added various concen-
trations of luteolin to LPS-stimulated IKKc or IRAK-1
immunoprecipitated extracts and then determined IKK or
IRAK-1 activity in a cell-free system. As shown in Fig. 4(d),
LPS-induced IKK activity, but not IRAK-1 autophosphory-
lation is blocked by luteolin in a dose-dependent manner
in a cell-free system. This suggests that luteolin prevents
LPS signalling to NF-jB through the direct blockade of
IKK activity in IEC-18 cells.
Luteolin inhibits LPS-dependent NF-jB
transcriptional activity in BMDCs isolated from
cis-NF-jBEGFP
To expand this observation to another cell type, we stud-
ied the effects of luteolin on BMDCs. These cells play a
pivotal role in the induction and in the control of host
innate immune responses. To directly measure NF-jB
activity in vivo, we recently generated a transgenic mouse
expressing the EGFP under the transcriptional control of
NF-jB cis-elements (cis-NF-jBEGFP).31 Cells and tissues
derived from that mouse allow for the measurement of
NF-jB dependent transcription through the evaluation of
EGFP expression levels. BMDCs were isolated from the
cis-NF-jBEGFP mice, pretreated with various concentra-
tions of luteolin for 1 hr and then stimulated with LPS
(1 lg/ml) for an additional 18 hr followed by EGFP
quantification using a Gemini XS fluorescent microplate
reader. As shown in Fig. 5, luteolin significantly decreased
LPS-induced EGFP expression in BMDCs in a dose-
dependent manner. This suggests that luteolin-mediated
NF-jB inhibition is not cell-type specific and operates in
mouse primary cells.
We next investigated the effect of luteolin on LPS-
induced NF-jB signalling in BMDCs. IRAK-1 is a signal-
ling molecule involved in the IL-1R/TLR pathway that is
degraded following LPS and IL-1 stimulation.38 To
investigate the effect of luteolin on LPS-induced IRAK-1
degradation, BMDCs were pretreated (1 hr) with luteolin
(50 lm), stimulated with LPS (1 lg/ml) for various time
points and IRAK-1 protein levels were determined by
Western blot analysis. As seen in Fig. 6(a), IRAK-1 pro-
tein levels decreased in LPS-stimulated BMDCs and this
process was not affected by luteolin (1st panel). How-
ever, luteolin significantly blocked LPS-induced IjBa
phosphorylation/degradation in BMDCs (Fig. 6a, 2nd
and 3rd panels), without impairing the phosphorylation
of RelA, p38 (Fig. 6a, 4th and 5th panels) and JNK (data
not shown). Thus, similarly to IEC-18, luteolin blocks
LPS-induced NF-jB signalling through decreased IjB
phosphorylation and degradation. Consistent with the
findings presented in Fig. 2(a), luteolin did not signifi-
cantly impair LPS-induced p38 and RelA phosphory-
lation in BMDCs. Because luteolin directly blocked
LPS-induced IKK activity in IEC-18, we tested whether
this flavonoid exerts a similar effect in BMDCs. Interest-
ingly, luteolin treatment of IKK immunoprecipitates
dose-dependently inhibited kinase activity in BMDCs
(Fig. 6b). This indicates that luteolin blocks NF-jB activ-
ity by interfering with IKK activity in both IEC-18 cells
and BMDCs.
Luteolin blocks LPS-induced IL-12 p40 and
TNF-a in BMDCs isolated from cis-NF-jBEGFP and
IL-10–/– mice
We next verified the inhibitory effect of luteolin on LPS-
induced proinflammatory gene expression in BMDCs
isolated from cis-NF-jBEGFP mice. BMDCs were pretreat-
ed with luteolin (50 lm) for 1 hr, stimulated with LPS
(1 lg/ml) and then IL-12 p40 and TNF-a gene expression
measured by real-time semiquantitative RT–PCR and
ELISA. As expected, luteolin strongly inhibited LPS-
















































Figure 5. Luteolin inhibits LPS-dependent NF-jB transcriptional
activity in BMDCs isolated from cis-NF-jBEGFP. Bone marrow-
derived dendritic cells (BMDCs) isolated from cis-NF-jBEGFP mice
were pretreated with various concentrations of luteolin for 1 hr, and
then stimulated with LPS (1 lg/ml) for 18 hr. Cells were lysed using
Nonidet P-40 lysis buffer and EGFP levels measured using a Gemini
XS microplate reader. The results were normalized to protein extract
concentrations. The excitation and emission settings were 488 nm
and 509 nm, respectively. Data are expressed as percent changes over
control determined as the means of three independent experiments.
Veh, DMSO vehicle; Lut, Luteolin.
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BMDCs (Fig. 7a) Accordingly, LPS-induced IL-12 p40
and TNF-a secretion was dose-dependently inhibited in
luteolin-treated BMDCs (Fig. 7b, c).
Interleukin-10 gene deficient (IL-10–/–) mice develop a
spontaneous T helper 1-mediated colitis when housed
under specific pathogen-free (SPF) conditions,39 which is
in large part caused by the dysregulated production of
IL-12 by antigen-presenting cells.40 Moreover, LPS-
induced IL-12 p40 secretion is stronger in BMDCs isola-
ted from IL-10–/– mice than wild type mice.41 Thus, we
next tested the effect of luteolin in cells displaying dysreg-
ulated innate responses to LPS. Interestingly, luteolin
(50 lm) blocked LPS-induced IL-12 p40 and TNF-a pro-
tein secretion in BMDCs isolated from IL-10–/– mice
(Fig. 7d). To investigate whether inhibition of LPS-
induced proinflammatory gene expression by luteolin is
caused by cytotoxic effects, we measured luteolin-induced
cytotoxicity in LPS-stimulated BMDCs. Luteolin-treated
BMDCs (Fig. 7e) and IEC-18 cells exhibited minimal
cytotoxicity (data not shown) as compared to methanol-
treated control, suggesting that the flavonoid is not signi-
ficantly altering cell viability.
Luteolin blocked LPS-induced NF-jB activation in
peripheral blood mononuclear cells and splenocytes
in vivo
To test the physiological relevance of luteolin-mediated
inhibition of NF-jB activity in vivo, we used cis-NF-
jBEGFP transgenic mice. Mice were injected intraperitone-
ally (i.p) with DMSO vehicle or luteolin (02 mg/kg), and
2 hr later, injected i.p. with LPS (40 mg/kg) for 18 hr.
PBMCs and splenocytes were isolated and EGFP expres-
sion quantified by FACS analysis. EGFP expression levels
were strongly induced in both PBMC (29% versus 81%)
and splenocytes (14% versus 15%) in LPS-injected cis-
NF-jBEGFP transgenic mice (Fig. 8). Interestingly, luteolin
totally blocked LPS-induced EGFP expression in both
PBMC and splenocytes. These findings indicate that lute-
olin blocked LPS-induced NF-jB signalling both in vitro
and in vivo. This effect appears to be mediated through
direct inhibition of IKK activity.
Discussion
In this study, we investigated the impact of the flavonoid
luteolin on LPS signalling and elucidated the mechanism
of action using two different cell systems, IECs and
BMDCs. Both cell types are important players in the
regulation of intestinal homeostasis by virtue of their
abilities to produce proinflammatory mediators, activate
lamina propria mononuclear cells recruit peripheral
blood immune cells and present antigens.8,42 In this
study, luteolin strongly inhibited LPS-mediated NF-jB
activation in both IEC-18 and BMDCs. We found that
luteolin blocked LPS-induced IjBa phosphorylation/
degradation and RelA nuclear translocation. Interestingly,
LPS-induced RelA, JNK and p38 phosphorylation were
not inhibited in luteolin-treated cells. Also IRAK-1, a sig-
nalling molecule involved in TLR-4 pathway, is degraded
in LPS-stimulated BMDCs and that this process was not
affected by luteolin, which was confirmed by in vitro kin-
ase assay. These findings suggest then that luteolin is not
a general inhibitor of protein phosphorylation and also
indicate that this flavonoid acts down-stream of IRAK-1
but upstream of IjB phosphorylation. Cytokine and bac-
terial product signalling converge on the IKK complex to
trigger IjB phosphorylation and ultimately NF-jB activ-
ity in numerous cell systems. We recently found that
NIK strongly induced IKK activity and NF-jB transcrip-
tional activity in IECs.31 Using adenoviral gene delivery,
we found that luteolin blocked NIK-induced NF-jB tran-
scriptional activity in IEC-18 cells, suggesting that this
flavonoid mediates its suppressive effects downstream of


















Figure 6. Luteolin blocks LPS-induced IjBa phosphorylation/degra-
dation and IjB kinase activity directly. (a) BMDCs isolated from
cis-NF-jBEGFP mice were pretreated with luteolin (50 lm) for 1 hr,
and then stimulated with LPS (1 lg/ml) for various times
(0–60 min). Total protein was extracted, and 20 lg of protein was
subjected to SDS–PAGE followed by IRAK-1, phospho-IjBa, IjBa,
phospho-RelA, phospho-p38, p38, and b-actin immunoblotting
using the ECL technique. Results are representative of three inde-
pendent experiments. (b) BMDCs isolated from cis-NF-jBEGFP mice
were stimulated with LPS (1 lg/ml) for 30 min. Whole cell extracts
were immunoprecipitated with an anti-IKKc/protein-A beads, and
kinase reactions performed as described in the legend to Fig. 4.
These results are representative of two independent experiments.
Veh, DMSO vehicle; Lut, Luteolin.
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activity in vivo and in vitro in both IEC-18 and BMDCs,
this suggests that this flavonoid mainly mediates its
effects through this kinase complex. This is in line with
the inhibitory effect of luteolin on IL-1b, TNF-a and
LPS-induced ICAM-1 gene expression, which all utilize
IKK as a common signal transductor to induce NF-jB
activity.
Cytokine-induced NF-jB activity has been shown to
require the production of radical oxygen species in some
cell systems.43,44 Flavonoids possess antioxidant properties
which may in part explain their anti-inflammatory action.
However, the involvement of radical oxygen species
in signal-induced NF-jB activation is controversial and
the subject of intense debate.45–48 For example, a recent
report found that endogenously produced reactive oxygen
species failed to activate NF-jB and that the antioxidant
N-acetyl-l-cysteine and pyrrolidine dithiocarbamate inhi-
bit NF-jB activation independently of their antioxidative
properties.49 Thus, it appears unlikely that luteolin-medi-
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Figure 7. Luteolin blocks LPS-induced IL-12 p40 and TNF-a in BMDCs isolated from cis-NF-jBEGFP and IL-10–/– mice. (a) BMDCs isolated
from cis-NF-jBEGFP were pretreated with luteolin (50 lm) for 1 hr, and then stimulated with LPS (1 lg/ml) for 5 hr. Total RNA was extracted,
reverse-transcribed, and amplified using an ABI Prism sequence detection system and specific IL-12 p40 and TNF-a primers as described in
Materials and methods. (b–d) BMDCs isolated from cis-NF-jBEGFP (b, c) or from IL-10–/– (d) mice were pretreated with various concentrations
of luteolin for 1 hr, and then stimulated with LPS (1 lg/ml) for 24 hr. ELISAs for mouse IL-12 p40 and TNF-a were performed using culture
supernatants from luteolin-treated BMDCs. (e) BMDCs isolated from cis-NF-jBEGFP were pretreated with various concentrations of luteolin for
1 hr, and then stimulated with LPS (1 lg/ml) for 24 hr. Simultaneous two-colour fluorescence determination of live and dead cells was carried
out with two probes that measured two recognized parameters of cell viability: calcein AM for intracellular esterase activity and ethidium
homodimers for plasma membrane integrity. Cells were incubated with methanol (100%) for 30 min to generate a positive control for cell death.
Fluorescence in cell samples was measured with appropriate excitation and emission filters using a spectrofluorometer. The data shown are mean













































































































































Figure 8. Luteolin blocked LPS-induced NF-jB activation in periph-
eral blood mononuclear cells (PBMCs) and splenocytes in vivo.
Cis-NF-jBEGFP mice were pretreated intraperitoneally (i.p) with
DMSO vehicle or luteolin (02 mg/kg, 100 ll) for 2 hr prior to i.p.
challenge with LPS (40 mg/kg, 100 ll). Mice were killed 18 hr after
LPS administration. Isolation of PBMCs and splenocytes was per-
formed as described under Materials and methods. Cells were pellet-
ed, resuspended in FACS buffer, and EGFP expression was measured
on a FACscan using the FL1 channel to detect EGFP fluorescence.
The numbers represent the percentage of EGFP positive cells. These
results are representative of two independent experiments (n ¼ 4).
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Our data clearly show that luteolin directly interferes
with activation of IKK activity. This is consistent with a
recent finding showing inhibition of TNF-a-induced IKK
activity by luteolin in respiratory epithelial cells.50 The
IKK complex is controlled by the structural regulatory
protein IKKc, also known as NF-jB essential modifier
that directs the activation of the catalytic IKKa and IKKb
subunits, which then phosphorylates IjBa at serine resi-
due 32 and 36. The IKKa and IKKb subunits each con-
tain a protein kinase domain, leucine zipper motifs and
helix-loop-helix motifs whereas IKKc has three a-helical
regions capable of forming a coiled-coil which may help
in the recruitment of upstream IKK activators.51 The kin-
ase activity of IKKb, the predominant subunit involved in
signal-induced IjB phosphorylation, has been shown to
be dependent on phosphorylation of serine residues 177
and 181 present in the activation loop of the kinase
domain.52 In addition, interaction between the regulatory
IKKc and the catalytic IKKb subunit appears to be medi-
ated by a short length of amino acids (44–86).53 Although
luteolin directly blocks IKK activity, it is not clear whe-
ther this effect is mediated through decreased IKK phos-
phorylation and/or interference with the recruitment of
up-stream coactivators. Alternatively, luteolin may affect
critical residues present within the activation loop of the
kinase or may interfere with the ATP binding sites. Fur-
ther studies would be necessary to precisely identify the
molecular mechanism of luteolin-mediated inhibition.
Recent evidence indicates that phosphorylation of ser-
ines 276, 529 and 536 on RelA increase NF-jB transcrip-
tional activity.34,35,54–56 Interestingly, luteolin failed to
block LPS-induced RelA S536 phosphorylation in IEC
and BMDCs. This suggests that luteolin mainly modulates
NF-jB activity through RelA shuttling and likely not by
interfering with the transactivating ability of the subunit.
In addition, the lack of inhibitory effect on IRAK-1 auto-
phosphorylation and on p38 and JNK phosphorylation
indicates that luteolin is not a pan-kinase inhibitor but
rather exerts some level of specificity. IKK has been
shown to induce RelA phosphorylation at serine residue
536.55,57 Thus, the blockade of LPS-induced IKK activity
and IjBa phosphorylation mediated by luteolin, in the
absence of impaired RelA S536 phosphorylation is a sur-
prising finding. However, the IKK/RelA S536 phosphory-
lation axis is mostly observed in TNF-a treated cells.55,57
Although a recent paper showed a role for IKKb in LPS-
induced RelA S536 phosphorylation in mouse embryonic
fibroblasts,58 it is possible that LPS-induced IKK activity
and RelA phosphorylation are two uncoupled events and
that luteolin selectively interferes with the former in IECs
and BMDCs. Further investigation will be necessary to
identify the kinase responsible for RelA S536 phosphory-
lation in these cells.
Dysregulated innate responses to the endogenous micro-
flora are a hallmark of intestinal inflammation such as that
observed in IBD and blockade of innate signal transduction
may help restore host homeostasis and alleviate inflamma-
tion.9,59 Using BMDCs isolated from IL-10–/– mice, which
develop a spontaneous IBD-like colitis, we show that luteo-
lin strongly inhibits LPS-induced IL-12 and TNF-a protein
secretion, two key mediators of intestinal inflammation in
IBD. This finding clearly indicates the potent down-modu-
lating effects of this flavonoid on proinflammatory gene
expression in disease relevant cells. Because luteolin evokes
minimal toxicity (< 11%) it is unlikely that blockade of
LPS-induced gene expression is caused by global decrease
in protein synthesis and/or increase in cell death.
To investigate the physiological impact of luteolin on
NF-jB activity in vivo, we used cis-NF-jBEGFP transgenic
mice recently engineered in our laboratory. This approach
allows the dynamic assessment of NF-jB activity through
measurement of EGFP expression levels. Using this
approach, we demonstrate for the first time that luteolin
blocks LPS-induced NF-jB activation in PBMCs and
splenocytes in vivo. Considering that LPS-mediated mul-
tiple organ dysfunction syndrome and septic shock have a
high mortality of up to 60% despite antibiotic therapy
and intensive care support,60 luteolin or other derivatives
may be possible candidate for the development of an
antisepsis agent. Further investigations are needed to clar-
ify the long-term effect of luteolin on immune cells and
vital end organs of endotoxaemic mice. We are currently
investigating the effect of luteolin on experimental models
of intestinal inflammation. In addition, this flavonoid
may have a beneficial impact on the prevention of cancers
and or as an adjuvant to chemotherapy in the treatment
of cancers. Future studies will examine the ability of lute-
olin to sensitive transformed cell lines and tumours to
chemotherapeutic agents. We are currently testing the
effect of various plant extracts and pure compounds on
an animal model of colon cancer.
In conclusion, we demonstrate that luteolin blocks
LPS-induced NF-jB signalling and proinflammatory gene
expression in intestinal epithelial cells and dendritic cells
through the inhibition of IKK activity. Modulation of
innate immunity by compounds isolated from natural
plant extracts may represent an attractive strategy towards
the prevention and treatment of intestinal and systemic
inflammation associated with dysregulated innate immune
responses.
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